Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony

Details

Serval ID
serval:BIB_3F189131E9C4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony
Journal
European Heart Journal
Author(s)
Fruhwald  F. M., Fahrleitner-Pammer  A., Berger  R., Leyva  F., Freemantle  N., Erdmann  E., Gras  D., Kappenberger  L., Tavazzi  L., Daubert  J. C., Cleland  J. G.
ISSN
0195-668X (Print)
Publication state
Published
Issued date
07/2007
Volume
28
Number
13
Pages
1592-7
Notes
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Jul
Abstract
AIMS: The Cardiac Resynchronization-Heart Failure (CARE-HF) study demonstrated that cardiac resynchronization therapy (CRT) could reduce morbidity and mortality and improve cardiac function in patients with moderate or severe heart failure secondary to left ventricular systolic dysfunction and markers of cardiac dyssynchrony. The purpose of this analysis was to investigate the effect of CRT on plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-pro-BNP), a powerful marker of cardiac dysfunction and prognosis. METHODS AND RESULTS: Blood samples were collected routinely at baseline and 3 and 18 months. Plasma was separated by cool centrifugation and stored at -70 degrees C until transported to a central laboratory for analysis of NT-pro-BNP using a standard commercial assay. Cardiac function was assessed echocardiographically. At baseline, median plasma concentration of NT-pro-BNP was similar in patients assigned to CRT or medical therapy [1920 pg/mL (inter-quartile range (IQR) 744-4288) and 1809 pg/mL (IQR 719-3949), respectively]. The differences in medians between the CRT and medical therapy groups were highly significant at both 3 months (537 pg/mL; P < 0.0001) and 18 months of follow-up (567 pg/mL; P < 0.0001). These differences could not be accounted for by changes in pharmacological therapy or renal function but were associated with improvement in ventricular volumes and function. CONCLUSION: CRT exerts an early and sustained reduction in NT-pro-BNP. This appears to reflect improvements in ventricular function. NT-pro-BNP may be a simple method for monitoring the effects of CRT.
Keywords
Aged Arrhythmia/blood/complications/*therapy Cardiac Pacing, Artificial/*methods Female Heart Failure, Congestive/blood/complications/*therapy Humans Male Middle Aged Natriuretic Peptide, Brain/*metabolism Peptide Fragments/*metabolism Ventricular Dysfunction, Left/blood/complications/*therapy
Pubmed
Web of science
Open Access
Yes
Create date
15/02/2008 11:28
Last modification date
20/08/2019 13:36
Usage data